JP2019510796A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510796A5 JP2019510796A5 JP2018552758A JP2018552758A JP2019510796A5 JP 2019510796 A5 JP2019510796 A5 JP 2019510796A5 JP 2018552758 A JP2018552758 A JP 2018552758A JP 2018552758 A JP2018552758 A JP 2018552758A JP 2019510796 A5 JP2019510796 A5 JP 2019510796A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- amino
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*c1ccc(*)c2c1[n](*C(CC1)CCC1*[n]1c(NC(c([n](*)nc3*)c3ClC(CC3)CCC3*[n]3nc(*)c(*)c3C(N3)=C)=O)nc4c1c(*C)ccc4*)c3n2 Chemical compound C*c1ccc(*)c2c1[n](*C(CC1)CCC1*[n]1c(NC(c([n](*)nc3*)c3ClC(CC3)CCC3*[n]3nc(*)c(*)c3C(N3)=C)=O)nc4c1c(*C)ccc4*)c3n2 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319358P | 2016-04-07 | 2016-04-07 | |
| US62/319,358 | 2016-04-07 | ||
| US201762461301P | 2017-02-21 | 2017-02-21 | |
| US62/461,301 | 2017-02-21 | ||
| US201762461975P | 2017-02-22 | 2017-02-22 | |
| US62/461,975 | 2017-02-22 | ||
| PCT/IB2017/051945 WO2017175147A1 (en) | 2016-04-07 | 2017-04-05 | Heterocyclic amides useful as protein modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020030908A Division JP6861307B2 (ja) | 2016-04-07 | 2020-02-26 | タンパク質調節因子として有用な複素環式アミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510796A JP2019510796A (ja) | 2019-04-18 |
| JP2019510796A5 true JP2019510796A5 (enExample) | 2020-04-09 |
| JP6746712B2 JP6746712B2 (ja) | 2020-08-26 |
Family
ID=58503675
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552758A Active JP6746712B2 (ja) | 2016-04-07 | 2017-04-05 | タンパク質調節因子として有用な複素環式アミド |
| JP2020030908A Active JP6861307B2 (ja) | 2016-04-07 | 2020-02-26 | タンパク質調節因子として有用な複素環式アミド |
| JP2021054203A Active JP7119158B2 (ja) | 2016-04-07 | 2021-03-26 | タンパク質調節因子として有用な複素環式アミド |
| JP2022122895A Active JP7466596B2 (ja) | 2016-04-07 | 2022-08-01 | タンパク質調節因子として有用な複素環式アミド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020030908A Active JP6861307B2 (ja) | 2016-04-07 | 2020-02-26 | タンパク質調節因子として有用な複素環式アミド |
| JP2021054203A Active JP7119158B2 (ja) | 2016-04-07 | 2021-03-26 | タンパク質調節因子として有用な複素環式アミド |
| JP2022122895A Active JP7466596B2 (ja) | 2016-04-07 | 2022-08-01 | タンパク質調節因子として有用な複素環式アミド |
Country Status (33)
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| MA42608A (fr) | 2015-08-13 | 2018-06-20 | Merck Sharp & Dohme | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
| EP3429596B1 (en) | 2016-03-18 | 2022-08-31 | Immune Sensor, LLC | Cyclic di-nucleotide compounds and methods of use |
| PE20181884A1 (es) * | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| RS62410B1 (sr) | 2016-10-04 | 2021-10-29 | Merck Sharp & Dohme | Benzo[b]tiofenska jedinjenja kao agonisti sting |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| AU2018246806B2 (en) | 2017-03-29 | 2022-05-12 | Ligachem Biosciences Inc. | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof |
| MX2019012233A (es) | 2017-04-13 | 2020-01-14 | Aduro Biotech Holdings Europe Bv | Anticuerpos anti-sirpa. |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| WO2019027857A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| EP3692033A1 (en) * | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
| CN111417630B (zh) * | 2017-10-05 | 2023-06-06 | 葛兰素史克知识产权开发有限公司 | 干扰素基因刺激因子(sting)的调节剂 |
| CN111194214A (zh) * | 2017-10-05 | 2020-05-22 | 葛兰素史密斯克莱知识产权发展有限公司 | 施用sting激动剂的方法 |
| MX2020004858A (es) | 2017-11-10 | 2020-10-01 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso. |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| WO2019134707A1 (zh) * | 2018-01-08 | 2019-07-11 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN110016025B (zh) * | 2018-01-08 | 2021-08-06 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112105357A (zh) * | 2018-02-16 | 2020-12-18 | Ucb生物制药有限责任公司 | 药用6,5杂双环衍生物 |
| EP3768266A4 (en) * | 2018-03-20 | 2021-12-22 | Merck Sharp & Dohme Corp. | OXO-TETRAHYDRO-ISOCHINOLINE-CARBOXYLIC ACIDS AS STING INHIBITORS |
| TW202003032A (zh) | 2018-03-23 | 2020-01-16 | 美商科迪亞克生物科學公司 | 包含ｓ ｔ ｉ ｎ ｇ 促效劑之胞外囊泡 |
| WO2019195124A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
| WO2019195063A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| US10947227B2 (en) | 2018-05-25 | 2021-03-16 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
| KR20210025016A (ko) * | 2018-06-28 | 2021-03-08 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 접합 삼중고리형 헤테로사이클 화합물과 그 치료 용도 |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
| WO2020038387A1 (zh) | 2018-08-24 | 2020-02-27 | 杭州阿诺生物医药科技有限公司 | 高活性sting蛋白激动剂 |
| MA53438A (fr) | 2018-08-24 | 2021-09-15 | Codiak Biosciences Inc | Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées |
| CN112608331B (zh) * | 2018-08-29 | 2022-03-11 | 杭州阿诺生物医药科技有限公司 | 中间体及其在合成sting蛋白激动剂化合物中的应用 |
| CN118878620A (zh) | 2018-09-06 | 2024-11-01 | 第一三共株式会社 | 环状二核苷酸衍生物及抗体药物偶联物的制造方法 |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| ES2959804T3 (es) | 2018-12-06 | 2024-02-28 | Glaxosmithkline Ip Dev Ltd | Nueva formulación farmacéutica que comprende un modulador de STING |
| US20220056044A1 (en) * | 2018-12-14 | 2022-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| WO2020132566A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting pyrazole agonists and uses thereof |
| WO2020146237A1 (en) * | 2019-01-07 | 2020-07-16 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020151682A1 (zh) * | 2019-01-23 | 2020-07-30 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| US20220119379A1 (en) * | 2019-01-31 | 2022-04-21 | Hitgen Inc. | Immunomodulator |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| BR112021018694A2 (pt) | 2019-03-21 | 2021-11-30 | Codiak Biosciences Inc | Vesículas extracelulares para distribuição de vacina |
| US20240108747A1 (en) | 2019-03-21 | 2024-04-04 | Lonza Sales Ag | Extracellular vesicle conjugates and uses thereof |
| BR112021018947A2 (pt) | 2019-03-28 | 2022-02-08 | Lupin Ltd | Compostos macrocíclicos como agonistas de sting |
| TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| WO2021000770A1 (zh) * | 2019-07-02 | 2021-01-07 | 凯复制药有限公司 | 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用 |
| WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GEP20247627B (en) | 2019-07-22 | 2024-05-27 | Lupin Ltd | Macrocyclic compounds as sting agonists and methods and uses thereof |
| CN112279835B (zh) * | 2019-07-24 | 2022-07-22 | 中国医学科学院药物研究所 | 芳环或芳杂环并咪唑类化合物，其制备方法及制药用途 |
| US12435104B2 (en) | 2019-07-25 | 2025-10-07 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
| TWI902699B (zh) * | 2019-07-25 | 2025-11-01 | 大陸商上海濟煜醫藥科技有限公司 | 雜環醯胺類化合物及其製備方法和應用 |
| KR20220056176A (ko) * | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| CN112521394A (zh) * | 2019-09-19 | 2021-03-19 | 中国药科大学 | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 |
| CN112521371B (zh) * | 2019-09-19 | 2022-11-25 | 中国药科大学 | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 |
| US20230241089A1 (en) | 2019-09-25 | 2023-08-03 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| EP4034081A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Extracellular vesicle compositions |
| JP2022551420A (ja) | 2019-09-25 | 2022-12-09 | コディアック バイオサイエンシーズ， インコーポレイテッド | 腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用 |
| EP4034276A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
| CN114555602B (zh) * | 2019-10-10 | 2024-02-06 | 百济神州有限公司 | 作为sting调节剂的杂环化合物 |
| AU2020368393B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| CN116813647B (zh) * | 2019-11-02 | 2025-08-01 | 上海凌达生物医药有限公司 | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 |
| CN112940004B (zh) * | 2019-12-11 | 2022-07-12 | 中国科学院上海药物研究所 | 一种杂环化合物及其用途 |
| CN114981265B (zh) * | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| CN113087668B (zh) * | 2019-12-23 | 2022-11-04 | 中国科学院上海药物研究所 | 一类苯并咪唑二聚体、其制备方法及用途 |
| CN113248475B (zh) * | 2020-02-11 | 2023-03-17 | 中国科学院上海药物研究所 | 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途 |
| PH12022551961A1 (en) | 2020-03-06 | 2023-10-09 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| US20230114434A1 (en) | 2020-03-13 | 2023-04-13 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| AU2021236763A1 (en) | 2020-03-20 | 2022-10-06 | Lonza Sales Ag | Extracellular vesicles for therapy |
| AU2021248635B2 (en) * | 2020-04-02 | 2025-10-23 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising STING agonists |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| AU2021338014A1 (en) | 2020-09-02 | 2023-03-09 | Daiichi Sankyo Company, Limited | Novel endo-β-N-acetylglucosaminidase |
| JP2023539526A (ja) * | 2020-09-02 | 2023-09-14 | ザ スクリプス リサーチ インスティテュート | インターフェロン遺伝子刺激因子ｓｔｉｎｇのアゴニスト |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| EP4216993A2 (en) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
| EP4240488A1 (en) | 2020-11-09 | 2023-09-13 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| AU2022208054A1 (en) | 2021-01-15 | 2023-07-27 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| CN112920172B (zh) * | 2021-02-01 | 2022-03-22 | 厦门大学 | 一种干扰素刺激蛋白靶向化合物、其放射性标记物、及它们的制备方法与应用 |
| WO2022177307A1 (ko) * | 2021-02-17 | 2022-08-25 | 한국화학연구원 | 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| KR102881036B1 (ko) * | 2021-02-17 | 2025-11-05 | 한국화학연구원 | 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| JP2024514707A (ja) | 2021-04-20 | 2024-04-02 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
| US20240285755A1 (en) | 2021-05-24 | 2024-08-29 | Glaxosmithkline Biologicals Sa | Adjuvants |
| WO2022246597A1 (en) * | 2021-05-24 | 2022-12-01 | Forever Millets Limited | Imidazopyridine derivatives as sting agonists |
| US20250057967A2 (en) * | 2021-06-25 | 2025-02-20 | Bolt Biotherapeutics, Inc. | Bis-benzimidazole sting agonist immunoconjugates, and uses thereof |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| CN115724838A (zh) * | 2021-08-26 | 2023-03-03 | 成都先导药物开发股份有限公司 | 一种适合作为抗体偶联药物效应分子的sting激动剂 |
| WO2023056468A1 (en) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| WO2023136589A1 (en) * | 2022-01-11 | 2023-07-20 | Bisichem Co., Ltd. | Fused heteroaryl hydroxamates as sting agonists |
| JP2025506393A (ja) * | 2022-02-02 | 2025-03-11 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのイミダゾールマクロサイクル |
| CN118742328A (zh) | 2022-02-22 | 2024-10-01 | 阿拉里斯生物技术股份公司 | 包含两个或更多个有效载荷的肽接头 |
| JPWO2023167238A1 (enExample) | 2022-03-02 | 2023-09-07 | ||
| WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
| JP2025525406A (ja) | 2022-07-05 | 2025-08-05 | ファイザー・インク | ピリド［４，３－ｄ］ピリミジン化合物 |
| KR20250054799A (ko) | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| EP4598901A1 (en) * | 2022-10-03 | 2025-08-13 | Thomas Jefferson University | Pyrrolidine and imidazolidine based dna polymerase theta inhibitors and use thereof |
| WO2024074977A1 (en) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
| EP4604961A1 (en) | 2022-10-18 | 2025-08-27 | Pfizer Inc. | Compounds for the treatment of cancer |
| WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| CN120981451A (zh) | 2023-02-27 | 2025-11-18 | 百欧恩泰欧洲股份公司 | 含有酰肼、肼和异羟肟酸官能团的sting激动剂 |
| WO2024180103A1 (en) | 2023-02-27 | 2024-09-06 | BioNTech SE | Sting agonists containing benzylic alcohol and benzylic amine functional groups |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2024209339A1 (en) | 2023-04-05 | 2024-10-10 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024213979A1 (en) | 2023-04-10 | 2024-10-17 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2025012195A1 (en) * | 2023-07-10 | 2025-01-16 | F. Hoffmann-La Roche Ag | Bicyclic macrocycles for the treatment of autoimmune disease |
| WO2025029832A2 (en) * | 2023-07-31 | 2025-02-06 | Sutro Biopharma, Inc. | Sting agonist compounds and conjugates |
| KR20250040871A (ko) * | 2023-09-15 | 2025-03-25 | 삼진제약주식회사 | Sting(인터페론 유전자 자극인자) 활성화제로서의 헤테로 고리 유도체 및 이를 포함하는 약학적 조성물 |
| EP4534147A1 (en) | 2023-10-05 | 2025-04-09 | Sulis Therapeutics ApS | Sting antagonist compounds |
| WO2025094035A1 (en) | 2023-11-01 | 2025-05-08 | Pfizer Inc. | Toll-like receptor agonists and conjugates thereof |
| EP4663632A1 (en) * | 2024-06-13 | 2025-12-17 | Sulis Therapeutics ApS | Compounds useful for the modulation of the activity of sting |
| EP4663204A1 (en) | 2024-06-13 | 2025-12-17 | Sulis Therapeutics ApS | Compounds useful for the modulation of the activity of sting |
| WO2026027944A1 (en) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
| WO2026055185A1 (en) | 2024-09-04 | 2026-03-12 | Bolt Biotherapeutics, Inc. | Sting agonist immunoconjugates and uses thereof |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| CA2310896A1 (en) | 1999-07-02 | 2001-01-02 | Japan Tobacco Inc. | Hcv polymerase suitable for crystal structure analysis and method for using the enzyme |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
| ATE395923T1 (de) | 2000-05-19 | 2008-06-15 | Corixa Corp | Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP1311522B1 (en) | 2000-08-04 | 2006-03-22 | Corixa Corporation | New immunoeffector compounds |
| US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
| DZ3487A1 (fr) | 2001-01-22 | 2002-07-25 | Merck Sharp & Dohme | Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| NZ528270A (en) | 2001-03-19 | 2005-10-28 | Ono Pharmaceutical Co | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| CA2481502A1 (en) | 2002-04-04 | 2003-10-16 | Achillion Pharmaceuticals, Inc. | Hcv antiviral and cytotoxicity drug screening assay |
| DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| PL376454A1 (en) | 2002-10-24 | 2005-12-27 | Glaxo Group Limited | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
| WO2004041201A2 (en) | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| ATE384724T1 (de) | 2002-12-13 | 2008-02-15 | Smithkline Beecham Corp | Cyclopropylverbindungen als ccr5 antagonisten |
| EP1569647B1 (en) | 2002-12-13 | 2008-08-20 | Smithkline Beecham Corporation | Cyclohexyl compounds as ccr5 antagonists |
| AU2003300902A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Piperidine derivatives as CCR5 antagonists |
| DE60324014D1 (de) | 2002-12-13 | 2008-11-20 | Smithkline Beecham Corp | Heterocyclische verbindungen alsccr5-antagonisten |
| JP2006512339A (ja) | 2002-12-13 | 2006-04-13 | スミスクライン ビーチャム コーポレーション | Ｃｃｒ５アンタゴニストとしてのインダン化合物 |
| AU2003296992A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Pyrrolidine and azetidine compounds as ccr5 antagonists |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| BRPI0413234A (pt) | 2003-08-01 | 2006-10-03 | Genelabs Tech Inc | derivados de imidazola bicìclica contra flaviviridae |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| US20050176792A1 (en) | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| WO2005073224A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
| TWI368507B (en) | 2004-02-20 | 2012-07-21 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
| JP4887284B2 (ja) | 2004-03-15 | 2012-02-29 | デイビッド・ケイ・アール・カラオリス | 癌細胞の増殖を阻害するための、または癌細胞のアポトーシスを増大させるための方法 |
| JP2007534735A (ja) | 2004-04-28 | 2007-11-29 | アロウ セラピューティクス リミテッド | 抗ウイルス剤として使用するためのモルホリニルアニリノキナゾリン誘導体 |
| TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AP2313A (en) | 2004-08-18 | 2011-10-31 | Pfizer | Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same. |
| GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| US20070060589A1 (en) * | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| CN101189230A (zh) | 2005-05-04 | 2008-05-28 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的杂环化合物 |
| KR20080019213A (ko) | 2005-05-09 | 2008-03-03 | 아칠리온 파르마세우티칼스 인코포레이티드 | 티아졸 화합물 및 그 사용방법 |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| RS52711B (sr) | 2005-05-10 | 2013-08-30 | Incyte Corporation | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5575636B2 (ja) | 2007-05-07 | 2014-08-20 | メディミューン，エルエルシー | 抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用 |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| HUE032735T2 (en) | 2007-12-14 | 2017-10-30 | Bristol Myers Squibb Co | Binding molecules for the human OX40 receptor |
| US8071766B2 (en) | 2008-02-01 | 2011-12-06 | Takeda Pharmaceutical Company Limited | HSP90 inhibitors |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CA2724430A1 (en) * | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| WO2013166000A1 (en) | 2012-04-30 | 2013-11-07 | Barber Glen N | Modulating immune responses |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| PE20120773A1 (es) | 2009-03-27 | 2012-07-19 | Presidio Pharmaceuticals Inc | Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091446A1 (en) * | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| BR112012024380A2 (pt) * | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
| UY33288A (es) * | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| ES2715611T3 (es) | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
| CN101898945B (zh) | 2010-07-27 | 2013-05-08 | 大连理工大学 | 盐析萃取发酵液中丙酮和丁醇的方法 |
| PL2609118T3 (pl) | 2010-08-23 | 2017-07-31 | Board Of Regents, The University Of Texas System | Przeciwciała anty-OX40 i sposoby ich stosowania |
| EP2651926A4 (en) | 2010-12-15 | 2014-07-09 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
| US9376493B2 (en) | 2011-03-31 | 2016-06-28 | INSERM (Institut National de la Sante et de la Recherche Mediacale) | Antibodies directed against ICOS and uses thereof |
| EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| KR101685262B1 (ko) | 2011-08-23 | 2016-12-21 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-ｏｘ４０ 항체 및 이의 사용 방법 |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック，インコーポレイテッド | 癌免疫療法のための組成物および方法 |
| KR102155559B1 (ko) * | 2012-06-27 | 2020-09-15 | 4에스체 악티엔게젤샤프트 | 암, 자가면역성 염증 및 중추신경계 장애를 치료하기 위한 비플루오로디옥살란-아미노-벤즈이미다졸 키나제 억제제 |
| US9695247B2 (en) | 2012-09-03 | 2017-07-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies directed against ICOS for treating graft-versus-host disease |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| MX361680B (es) | 2012-12-13 | 2018-12-13 | Aduro Biotech Inc | Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso. |
| ES2754269T3 (es) | 2013-05-18 | 2020-04-16 | Aduro Biotech Inc | Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
| EP3149195B1 (en) | 2014-06-02 | 2018-12-05 | Base4 Innovation Ltd | Nucleotide polymorphism detection method |
| CR20160564A (es) * | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| BR112017000497B1 (pt) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| KR20170129902A (ko) | 2015-03-23 | 2017-11-27 | 조운스 테라퓨틱스, 인크. | Icos에 대한 항체 |
| MA42608A (fr) | 2015-08-13 | 2018-06-20 | Merck Sharp & Dohme | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
| CA3006930A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| PE20181884A1 (es) | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| ES2781474T3 (es) * | 2016-04-07 | 2020-09-02 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
-
2017
- 2017-04-05 PE PE2018001834A patent/PE20181884A1/es unknown
- 2017-04-05 NZ NZ745957A patent/NZ745957A/en unknown
- 2017-04-05 MY MYPI2018703686A patent/MY189100A/en unknown
- 2017-04-05 IL IL285702A patent/IL285702B/en unknown
- 2017-04-05 LT LTEPPCT/IB2017/051945T patent/LT3440076T/lt unknown
- 2017-04-05 CN CN201780022379.8A patent/CN109071514B/zh active Active
- 2017-04-05 PT PT177163128T patent/PT3440076T/pt unknown
- 2017-04-05 SG SG10201900629VA patent/SG10201900629VA/en unknown
- 2017-04-05 PE PE2018002003A patent/PE20181919A1/es unknown
- 2017-04-05 IL IL295649A patent/IL295649B2/en unknown
- 2017-04-05 HR HRP20220936TT patent/HRP20220936T1/hr unknown
- 2017-04-05 MX MX2020009947A patent/MX387354B/es unknown
- 2017-04-05 CN CN202110799242.1A patent/CN113549110B/zh active Active
- 2017-04-05 AU AU2017247798A patent/AU2017247798C1/en active Active
- 2017-04-05 US US16/091,189 patent/US10981901B1/en active Active
- 2017-04-05 UA UAA201810983A patent/UA123407C2/uk unknown
- 2017-04-05 DK DK17716312.8T patent/DK3440076T3/da active
- 2017-04-05 CA CA3019630A patent/CA3019630A1/en active Pending
- 2017-04-05 SG SG11201808621TA patent/SG11201808621TA/en unknown
- 2017-04-05 CN CN201811311714.9A patent/CN109608443B/zh active Active
- 2017-04-05 CR CR20200045A patent/CR20200045A/es unknown
- 2017-04-05 EP EP17716312.8A patent/EP3440076B1/en active Active
- 2017-04-05 PL PL17716312.8T patent/PL3440076T3/pl unknown
- 2017-04-05 KR KR1020187032396A patent/KR102527784B1/ko active Active
- 2017-04-05 KR KR1020187031915A patent/KR102527786B1/ko active Active
- 2017-04-05 RS RS20220734A patent/RS63462B1/sr unknown
- 2017-04-05 SM SM20220339T patent/SMT202200339T1/it unknown
- 2017-04-05 JP JP2018552758A patent/JP6746712B2/ja active Active
- 2017-04-05 WO PCT/IB2017/051945 patent/WO2017175147A1/en not_active Ceased
- 2017-04-05 UY UY0001037195A patent/UY37195A/es unknown
- 2017-04-05 EP EP22159533.3A patent/EP4032885A1/en active Pending
- 2017-04-05 JO JOP/2017/0083A patent/JOP20170083B1/ar active
- 2017-04-05 ES ES17716312T patent/ES2921855T3/es active Active
- 2017-04-05 SI SI201731184T patent/SI3440076T1/sl unknown
- 2017-04-05 MX MX2018012333A patent/MX379169B/es unknown
- 2017-04-05 PE PE2018002322A patent/PE20181920A1/es unknown
- 2017-04-05 CR CR20200044A patent/CR20200044A/es unknown
- 2017-04-05 SG SG10201900628RA patent/SG10201900628RA/en unknown
- 2017-04-05 MX MX2020009948A patent/MX387353B/es unknown
- 2017-04-05 HU HUE17716312A patent/HUE058932T2/hu unknown
- 2017-04-06 TW TW111130004A patent/TWI868471B/zh active
- 2017-04-06 TW TW107147613A patent/TWI777014B/zh active
- 2017-04-06 TW TW106111324A patent/TWI776806B/zh active
-
2018
- 2018-01-03 US US15/730,664 patent/US10189820B2/en active Active
- 2018-08-30 IL IL261482A patent/IL261482B/en unknown
- 2018-09-06 IL IL261657A patent/IL261657B/en unknown
- 2018-09-13 AU AU2018229497A patent/AU2018229497C1/en active Active
- 2018-09-13 AU AU2018229498A patent/AU2018229498C1/en active Active
- 2018-10-04 CO CONC2018/0010727A patent/CO2018010727A2/es unknown
- 2018-10-04 DO DO2018000217A patent/DOP2018000217A/es unknown
- 2018-10-05 PH PH12018502151A patent/PH12018502151B1/en unknown
- 2018-10-05 CL CL2018002850A patent/CL2018002850A1/es unknown
- 2018-10-11 PH PH12018502179A patent/PH12018502179A1/en unknown
- 2018-10-15 PH PH12018502202A patent/PH12018502202A1/en unknown
- 2018-11-20 CL CL2018003291A patent/CL2018003291A1/es unknown
- 2018-11-20 CL CL2018003290A patent/CL2018003290A1/es unknown
-
2020
- 2020-01-30 DO DO2020000019A patent/DOP2020000019A/es unknown
- 2020-01-30 AU AU2020200692A patent/AU2020200692C1/en active Active
- 2020-01-30 DO DO2020000018A patent/DOP2020000018A/es unknown
- 2020-02-26 JP JP2020030908A patent/JP6861307B2/ja active Active
-
2021
- 2021-01-25 US US17/156,893 patent/US11365190B2/en active Active
- 2021-03-26 JP JP2021054203A patent/JP7119158B2/ja active Active
-
2022
- 2022-05-17 US US17/663,749 patent/US11970480B2/en active Active
- 2022-08-01 JP JP2022122895A patent/JP7466596B2/ja active Active